BioArctic AB (publ)

Price Chart

Risk-Adjusted Performance

Also Listed On

BioArctic AB (publ) (BIOA-B) Price Performance

BioArctic AB (publ) (BIOA-B) trades on Nasdaq Stockholm in SEK. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at SEK321.40, down 2.31% from the previous close.

Over the past year, BIOA-B has traded between a low of SEK172.00 and a high of SEK364.40. The stock has gained 81.4% over this period. It is currently 11.8% below its 52-week high.

BioArctic AB (publ) has a market capitalization of $29.84B, with a price-to-earnings ratio of 29.24.

About BioArctic AB (publ)

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

Compare BioArctic AB (publ)

Side-by-side comparison against top Healthcare peers.